发明名称 |
Purified APO A and APO E compounds and methods for using them |
摘要 |
A substantially endotoxin-free ApoA or ApoE is produced by recombinant DNA technique, suitably in E. coli. Medicaments and methods for treatment of atherosclerosis or cardiovascular diseases employ ApoA or ApoE purified by a process comprising contacting a first aqueous solution comprising ApoA or ApoE and endotoxins with a matrix comprising an immobilized compound with an end group comprising two or three nitrogen atoms bonded to a carbon atom for attaching the endotoxins to the matrix, and subsequently treating the matrix comprising the immobilized compound with a second aqueous solution comprising a surfactant for releasing the ApoA or ApoE while the endotoxins remain attached to the matrix. Alternatively, the ApoA or ApoE is purified by a process comprising contacting the first aqueous solution comprising ApoA or ApoE and endotoxins with an anion-exchange matrix for attaching the ApoA and ApoE to the matrix, treating the anion-exchange matrix with a second aqueous solution comprising a compound comprising two or three nitrogen atoms bonded to a carbon atom for releasing the endotoxins while the ApoA or ApoE remains attached to the matrix, and then releasing the ApoA or ApoE from the matrix.
|
申请公布号 |
US5990081(A) |
申请公布日期 |
1999.11.23 |
申请号 |
US19980129720 |
申请日期 |
1998.08.05 |
申请人 |
ESPERION THERAPEUTICS, INC. |
发明人 |
AGELAND, HANS;ROMANDER, LENA |
分类号 |
C12N15/09;A61K38/00;A61K47/48;A61P9/00;C07K1/18;C07K1/22;C07K1/36;C07K14/775;C12P21/00;C12R1/19;(IPC1-7):A61K38/00;C07K1/00 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|